Drug Safety

, Volume 5, Supplement 1, pp 95–100 | Cite as

Non-Medicinal Ingredients

  • Alexander W. M. Scott


Many drug products contain excipients which perform important functions in terms of stability, solubility and identification. Excipients should not be considered as inactive ingredients, as they have been associated with a wide range of adverse reactions in some individuals. Monitoring for excipient toxicity is important. Equally important, is the provision of non-medicinal ingredient information on packaging, patient information leaflets and prescribing information, as most excipient-related toxicity is preventable when the formulation is known.


Atrovent Reporting Scheme Tartrazine Patient Information Leaflet Metabisulphite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brown E. Patient information leaflets: a progress report. British Institute of Regulatory Affairs 8 (2): in pressGoogle Scholar
  2. Clarke RSJ. Epidemiology of adverse reactions in anaesthesia in the United Kingdom. Klinische Wochenschrift 60: 1003–1005, 1982PubMedCrossRefGoogle Scholar
  3. Drug and Therapeutics Bulletin. Tartrazine: a yellow hazard. Drug Therapy Bulletin 19: 75, 1981Google Scholar
  4. Fisher AA. Dermatitis due to formaldehyde-releasing agents in cosmetics and medicaments. Cutis 22: 655, 1978PubMedGoogle Scholar
  5. Golightly LK, Smolinske SS, Bennett ML, Sutherland III EW, Rumack BH. Pharmaceutical excipients. Medical Toxicology 3: 128–165, 1988PubMedCrossRefGoogle Scholar
  6. Hoefnagels WAJ, Gerritsen EJA, Brouwer OF, Souverijn JHM. Cyclosporin encephalopathy associated with fat embolism induced by the drug’s solvent. Lancet 2: 901, 1988PubMedCrossRefGoogle Scholar
  7. Murdoch RD, Pollock I, Naeem S. Tartrazine induced histamine release in vivo in normal subjects. Journal of the Royal College of Physicians, London 21: 257–261, 1987Google Scholar
  8. O’Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in lung function after nebulised salbutamol in wheezy infants. Lancet 2: 1424–1425, 1986PubMedCrossRefGoogle Scholar
  9. Rawlins MD. Spontaneous reporting of adverse reactions. I. The data. British Journal of Clinical Pharmacology 26: 1–5, 1988aPubMedCrossRefGoogle Scholar
  10. Rawlins MD. Spontaneous reporting of adverse reactions. II. Uses. British Journal of Clinical Pharmacology 26: 7–11, 1988bPubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • Alexander W. M. Scott
    • 1
  1. 1.Department of HealthMedicines Control AgencyVauxhall, LondonUnited Kingdom

Personalised recommendations